China Approves Eli Lilly's Oral GLP-1 Weight-Loss Drug Orforglipron
Eli Lilly (LLY) has received regulatory approval from China's medicine regulator for its oral GLP-1 weight-loss medication, orforglipron. This milestone makes the company the first pharmaceutical manufacturer to secure clearance for an oral GLP-1 weight-loss pill in the Chinese market. The approval positions Eli Lilly ahead of its primary competitor, Novo Nordisk, in the race to capture the growing demand for oral obesity treatments in China. As the market shifts from injectable therapies toward more convenient oral alternatives, this regulatory win provides a significant competitive advantage in one of the world's largest pharmaceutical markets.
Topics: China Market GLP-1 Pharmaceuticals Weight Loss Drugs
Read the full article at Seeking Alpha
Part of the story Blackstone to provide Pfizer up to $1.5B to advance monthly GLP-1 for weight loss (3 articles)